Pfizer closes on buy of Encysive Jun 12, 2008
Last August, San Francisco-based Genentech Inc. closed on the $919 million acquisition of Houston-based Tanox Inc., which shuttered its operations here and moved them to California. Related Industry News. (Houston Business Journal, TX)
AIDS drug survives Tanox May 21, 2008
A promising HIV/AIDS treatment drug formerly in the Tanox Inc. fold remains in the Houston pipeline. TaiMed Biologics Inc. will conduct clinical trials of TNX-355 -- also known as Ibalizumab -- from a location on the West Loop near the former Tanox headquarters in suburban Bellaire. (Houston Business Journal, TX)
Achillion Appoints Gary E. Frashier to Board of Directors Apr 2, 2008
He is a former director of Aderis Pharmaceuticals, Maxim Pharmaceuticals, Merrimack Pharmaceuticals, eXegenics (formerly Cytoclonal Pharmaceutics Inc.), and Tanox Inc.. We are quite pleased to have Gary's broad experience available to us as Achillion moves forward with its growing pipeline. (Primezone Releases)
Encysive drug approval struggle to end with acquisition by Pfizer Feb 25, 2008
Last August, San Francisco-based Genentech Inc. closed on the $919 million acquisition of Houston-based Tanox Inc., which shuttered its operations here and moved them to California. This article is for Paid Print Subscribers ONLY.. (Houston Business Journal, TX)
Frank Liu planning to develop biotech park near Med Center Jan 21, 2008
Lovett Commercial, headed by Houston developer Frank Liu, is buying the former headquarter buildings of Tanox Inc. and 24 acres of vacant land for creation of a new biotechnology park a couple of miles from the Texas Medical Center. The buildings, which total 110,000 square feet, are located just south of the 610 Loop on Stella Link. (Houston Business Journal, TX)
* China's Wuxi agrees to buy AppTec Jan 5, 2008
Taipei Times - archives. Enter your search terms. (Taipei Times, Taiwan -- World)
Wuxi of China to Acquire AppTec Laboratory in Minnesota for $151 Million Jan 4, 2008
Hu, hired in August as executive vice president of operations, was formerly chief operating officer at Tanox Inc., a Houston-based biotechnology company acquired in August by Genentech Inc., based in South San Francisco, California. (The companies will hold a conference call at 8 a.m. New York time, accessible by dialing +1-888-262-8797. (Bloomberg -- Asia)
WuXi PharmaTech (NYSE: WX) Promotes Edward Hu to COO Jan 4, 2008
SHANGHAI, China, Jan. 3 /Xinhua-PRNewswire/ -- WuXi PharmaTech (NYSE: WX), China's premier provider of pharmaceutical Rourcing services is pleased to announce today that it has promoted Mr. Edward Hu from Executive Vice President of Operations to Chief Operating Officer. Prior to joining WuXi PharmaTech in August 2007, Mr. Hu was a senior vice president and Chief Operating Officer at Tanox, Inc., a NASDAQ listed company later acquired by Genentech, Inc. He also worked for Biogen Idec as a... (PR Newswire)
Genentech 3Q profit increases 21 percent, beating estimates Oct 17, 2007
Not counting expenses, including those related to the $919 million buyout of biotechnology company Tanox Inc. last quarter, the company earned $778 million, or 73 cents per share. On that basis, which does not comply with generally accepted accounting principles, analysts had expected Genentech to earn 72 cents per share on revenue of $2. (San Diego Union-Tribune -- Business)
Genentech's Q3 profit up 21% Oct 16, 2007
91 billion, which included recognition of $3 million of deferred royalty revenue associated with its $919 million buyout of biotechnology company Tanox Inc. during the quarter. In the same period last year the company's revenue was $2. (San Jose Business Journal)
Bombardier grounds turboprops Sep 13, 2007
Duncan previously worked in financial and operations management at companies including La Jolla Pharmaceutical, Tanox Inc. and Hybritech Inc. ... Duncan previously worked in financial and operations management at companies including La Jolla Pharmaceutical, Tanox Inc. and Hybritech Inc.. (San Diego Union-Tribune -- Business)
Genentech Completes Buyou Aug 4, 2007
Genentech completes acquisition / $919 million for Tanox is its first purchase ever (San Francisco Chronicle -- Technology)
HealthShares(TM) Announces Change to the HealthShares(TM) Respiratory/Pulmonary Index Aug 3, 2007
NEW YORK, Aug. 2 /PRNewswire/ -- HealthShares(TM) Inc., an investment company with a series of 20 underlying fund portfolios, today announced it has been informed by Standard s, the calculating agent for the HealthShares(TM) Indices, that effective at the opening of trading on Monday August 6, 2007, Matrixx Initiatives Inc. (Nasdaq: ) will replace Tanox Inc. (Nasdaq: ) in the HealthShares(TM) Respiratory/Pulmonary Index. Tanox Inc. is being dropped due to the acquisition of 100% of Tanox by... (PR Newswire)
PTV Sciences closes second fund Jun 15, 2007
PTV Sciences has also added two new members to its 14-member advisory board, including Nancy Chang, former president and CEO of Houston-based Tanox Inc. (NASDAQ: TNOX), and Dr. Stephen Slade, a Fellow of the American Academy of Ophthalmology and American College of Surgeons, who performed the first LASIK eye surgery procedure with Dr. Stephen Brint in 1991. Extra. (Houston Business Journal, TX)
Maquiladoras, Branch Banking, Biotechnology, Texas Exports Examined In Dallas Fed Report Apr 13, 2007
The dynamic U.S. biotech industry owes a great deal of its success to globalization, asserts Nancy Chang, Dallas Fed Houston Branch board member, in "Taking the Pulse of Biotech." Chang, chairman of biotech company Tanox Inc., says the world is now one big marketplace for the pharmaceutical industry. Many American biotechs have gone global to conduct drug tests and research because other countries often have fewer restrictions than the U.S. Also, the Internet has made research more accessible... (PR Newswire)
FTC asks for more info on Genentech, Tanox merger Jan 30, 2007
BOSTON Biotechnology company Genentech Inc. said Monday it has received a request for more information from federal antitrust authorities in connection its proposed $919 million acquisition of Tanox Inc.. The two companies said they continue to engage in active and productive discussions with the U.S. Federal Trade Commission and intend to cooperate fully with the FTC in its review of the proposed acquisition, which was approved by Tanox stockholders on Jan. 15. (San Diego Union-Tribune -- Business)
Tuesday's Stocks to Watch Jan 16, 2007
Shareholders of Tanox Inc. () have overwhelmingly approved an agreement providing for its acquisition by biotech bellwether Genentech (). The $20-a-share transaction's expected to be completed during the first quarter. (Fox News)
Tanox Shareholders OK Acquisition Jan 16, 2007
HOUSTON Jan 15, 2007 (AP) Shareholders of Tanox Inc. on Monday approved the tiny biotechnology company's acquisition by drug maker Genentech Inc., Tanox officials said. Under the terms of the sale, Genentech will buy Houston-based Tanox for $919 million, or $20 per share. (ABC News -- Wire)
Pfizer, Merck, Lilly `Arms Race' May Spur Biotechnology Purchases in 2007 Jan 13, 2007
Genentech Inc., the world's No. 2 biotechnology company, agreed to buy its partner Tanox Inc. in November, gaining the asthma medication Xolair. The $919 million transaction was the first acquisition in Genentech's history. (Bloomberg)
